Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
Another term for PBAC chair
March 26, 2019 - - Latest News -
Is this 'Factor F' or just another announcement?
March 26, 2019 - - Latest News -
Nominations open for research awards
March 26, 2019 - -
Biogen and Eisai scrap development of aducanumab
March 25, 2019 - - Latest News -
GSK locals join global colleagues in ‘Trek For Kids’
March 25, 2019 - - Latest News -
Greg Hunt seeks advice on pre-PBAC funding
March 25, 2019 - - Latest News -
Article cites unnamed 'experts' in PBS influence claims
March 25, 2019 - - Latest News